{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '3. STUDY OBJECTIVES', '3.1', 'Primary Objective', 'The primary objective of this study is to evaluate the long-term safety and tolerability of', 'OKZ 64 mg administered SC q2w or q4w in subjects with moderately to severely active RA', 'who previously completed 24 weeks of double-blind treatment in the core studies.', '3.2', 'Secondary Objectives', 'The secondary objectives of this study are as follows:', 'To evaluate the long-term efficacy of OKZ', 'To evaluate the long-term immunogenicity of OKZ', 'To evaluate the physical function and quality of life of subjects receiving long-term', 'treatment with OKZ', 'Amendment 2: 06 March 2019', '40', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '4. SUMMARY OF STUDY ENDPOINTS', 'The following safety, efficacy, and immunogenicity endpoints will be assessed to evaluate', 'long-term treatment with OKZ 64 mg q2w or OKZ 64 mg q4w.', '4.1', 'Safety Enppoints', 'The following safety endpoints will be evaluated:', 'Nature, incidence, severity, and outcome of AEs, including SAEs and AEs of special', 'interest (AESIs)', 'Follow-up-adjusted incidence rates (IR) and event rates (ER) (per 100 subject-years', '[SY] of follow-up) for SAEs and AESIs', 'Proportions of subjects with clinically significant laboratory abnormalities', 'Assessment of changes over time in clinical laboratory parameters, vital sign', 'measurements, and physical examination findings', 'Time from first exposure to OKZ to the first occurrence of any major adverse cardiac', 'event (MACE)', 'Incidence and titer of antidrug antibodies (ADAs) to OKZ, incidence of neutralizing', 'antibodies, and the time course of antibodies', '4.2', 'Efficacy Enppoints', 'For the efficacy endpoints, comparison will be made with Core Baseline values (i.e., Week 0', 'baseline values in the core study) and OLE Baseline values (i.e., Week 24 baseline values in', 'the OLE study) for most parameters, as defined in Section 9.4.1. For subjects from', 'Study CL04041025 who initiate OKZ treatment at Week 16 of the core study after having', 'completed 16 weeks of placebo treatment, changes from the last pre-OKZ value will also be', 'summarized.', 'The following efficacy endpoints will be evaluated:', 'Proportion of subjects achieving an ACR20, ACR50, and ACR70 response who', 'remain on randomized open-label treatment and in the study, assessed at all applicable', 'time points', 'Proportion of subjects with Simplified Disease Activity Index (SDAI) <3.3 remission,', 'who remain on randomized open-label treatment and in the study, assessed at all', 'applicable time points', 'Amendment 2: 06 March 2019', '41', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Proportion of subjects with Disease Activity Score 28-joint count (DAS28) low', 'disease activity (based on DAS28 C-reactive protein [CRP] <3.2), who remain on', 'randomized open-label treatment and in the study, assessed at all applicable time', 'points', 'Change from baseline over time in DAS28 (CRP), assessed at all applicable time', 'points', 'Change from baseline over time in the measure of physical ability based on Health', 'Assessment Questionnaire-Disability Index (HAQ-DI), assessed at all applicable time', 'points', 'Proportion of subjects with improvement from baseline in HAQ-DI score 0.22, who', 'remain on randomized open-label treatment and in the study, assessed at all applicable', 'time points', 'Change from baseline over time in the scores for the following patient-reported', 'outcomes (PRO) measures, assessed at all applicable time points:', '- Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component', 'Summary (MCS) total scores', '- European Quality of Life-5 Dimensions (EQ-5D)', '- Work Productivity Survey-Rheumatoid Arthritis (WPS-RA)', '- Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue)', 'Change from baseline over time in SDAI and Clinical Disease Activity Index (CDAI),', 'assessed at all applicable time points', 'Proportion of subjects with moderate to good responses for EULAR based on DAS28', '(CRP), who remain on randomized open-label treatment and in the study, assessed at', 'all applicable time points, where a moderate response is defined as either DAS28', '(CRP) <5.1 with an improvement from baseline in DAS28 (CRP) >0.6 and 1.2, or', 'DAS28 (CRP) >3.2 with an improvement from baseline in DAS28 (CRP) >1.2, and a', 'good response is defined as DAS28 (CRP) <3.2 with an improvement from baseline in', 'DAS28 (CRP) >1.2', 'Change from baseline to all time points in the components of the ACR response', 'criteria', 'Amendment 2: 06 March 2019', '42', 'Confidential']\n\n###\n\n", "completion": "END"}